By the way, I know. I actually miss Blinatumomab. It is such a difference between small biotech and big one like AMGN. We barely know/hear anything about what's going on with the drug.
True, but sometimes these things are a blessing. AMGN bought my holding Tularik many moons ago and I've not heard a peep about them since. Something tells me I should be happy with the premium gained and move on.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.